FDA approves first injectable treatment to prevent HIV infection
In December, the US Food and Drug Administration (FDA) approved an injectable form of GlaxoSmithKline’s (GSK) cabotegravir drug that is given every two months to prevent an HIV infection. The injection - Apretude - to prevent the virus that causes AIDS is aimed as an alternative to daily pills and has been approved for use in at-risk adults and adolescents. Its first two doses are administered one month apart and then the injection is given every two months thereafter.
The approval was based on a final study that found the drug 66% more effective in preventing HIV infections than Gilead’s Truvada daily oral pills.
Apretude comes with a boxed warning to not use the drug unless a negative HIV test is confirmed. Cabotegravir and the daily oral pill were both well tolerated in the study.